Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 +1.09%69 3-Year ROIIC % is 677.41 as of Mar. 2026, which is 3370% above its 10-year median of 19.52. GuruFocus rates BOM:531762 with a GF Score™ of 69/100 and a GF Value™ of ₹22.86 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, Unjha Formulations ranks better than 97.78% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Unjha Formulations's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 677.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Unjha Formulations's 3-Year ROIIC % or its related term are showing as below:
BOM:531762's 3-Year ROIIC % is ranked better than 97.78% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs BOM:531762: 677.41
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Unjha Formulations 3-Year ROIIC % Related Terms
Unjha Formulations 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's 3-Year ROIIC % falls into.
Unjha Formulations's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 5.895624 (Mar. 2026) - 3.0572757 (Mar. 2023) )
/
( 24.852 (Mar. 2026) - 24.433 (Mar. 2023) )
=
2.8383483
/
0.419
=
677.41%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Unjha Formulations (BOM:531762) has a 3-Year ROIIC % of 677.41 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Unjha Formulations and its competitors. This is 3370% above median its historical median of 19.52. According to the industry distribution chart, Unjha Formulations ranks #21 out of 944 companies in the Drug Manufacturers industry, placing it in the top 2.2%.
Is Unjha Formulations' 3-Year ROIIC % too high?
Unjha Formulations' current 3-Year ROIIC % of 677.41 is 3370% above median its 10-year median of 19.52. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Unjha Formulations' value of 677.41 is 18664.8% above this industry median. Based on the distribution chart, Unjha Formulations ranks #21 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Unjha Formulations has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #21 out of 944 companies for 3-Year ROIIC %. This places Unjha Formulations in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.61. Unjha Formulations' value of 677.41 is 18664.8% above this benchmark. While the company's 10-year median is 19.52 vs. the industry median of 3.61, Unjha Formulations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current 3-Year ROIIC % of 677.41 is 18664.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current 3-Year ROIIC % is 677.41, which is 3370% above median its own 10-year median of 19.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹22.86, compared to a current price of ₹29.19 — trading 27.7% above its estimated fair value. The current 3-Year ROIIC % is 677.41, which is 3370% above median its 10-year median of 19.52 and 18664.8% above the Drug Manufacturers industry median of 3.61. Unjha Formulations' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current 3-Year ROIIC % is 677.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹29.19 is trading 27.7% above its estimated GF Value™ of ₹22.86.
GuruFocus considers Unjha Formulations to be Modestly Overvalued.
Key valuation signals for BOM:531762:
3-Year ROIIC %: 677.41 (3370% above median its 10-year median of 19.52)
GF Value™: ₹22.86 vs. price of ₹29.19 (27.7% above fair value)
Industry Position: 18664.8% above the Drug Manufacturers median (#21 of 944)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
69GF Score
Get the complete analysis for BOM:531762
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
